Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Lessons learned from next-generation sequencing in head and neck cancer.

Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, Agrawal N.

Head Neck. 2013 Mar;35(3):454-63. doi: 10.1002/hed.23100. Epub 2012 Aug 21. Review.

2.

Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.

Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR; Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Human Immunodeficiency Virus (HIV) Supplement Consortium.

Cancer. 2018 Jan 1;124(1):84-94. doi: 10.1002/cncr.31063. Epub 2017 Oct 20.

PMID:
29053175
3.

Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.

van Ginkel JH, de Leng WW, de Bree R, van Es RJ, Willems SM.

Oncotarget. 2016 Sep 20;7(38):61575-61586. doi: 10.18632/oncotarget.11196.

4.

Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.

Tinhofer I, Budach V, Saki M, Konschak R, Niehr F, Jöhrens K, Weichert W, Linge A, Lohaus F, Krause M, Neumann K, Endris V, Sak A, Stuschke M, Balermpas P, Rödel C, Avlar M, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baumann M; DKTK-ROG.

Eur J Cancer. 2016 Apr;57:78-86. doi: 10.1016/j.ejca.2016.01.003. Epub 2016 Feb 18.

PMID:
26896955
5.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

6.

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.

Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG, Gutkind JS.

Oncotarget. 2014 Oct 15;5(19):8906-23.

7.

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.

Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN.

Science. 2011 Aug 26;333(6046):1154-7. doi: 10.1126/science.1206923. Epub 2011 Jul 28.

8.

Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.

Nichols AC, Yoo J, Palma DA, Fung K, Franklin JH, Koropatnick J, Mymryk JS, Batada NN, Barrett JW.

Arch Otolaryngol Head Neck Surg. 2012 Aug;138(8):732-9. doi: 10.1001/archoto.2012.1558.

PMID:
22911296
9.

Genomic analysis of metastatic cutaneous squamous cell carcinoma.

Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS.

Clin Cancer Res. 2015 Mar 15;21(6):1447-56. doi: 10.1158/1078-0432.CCR-14-1773. Epub 2015 Jan 14.

10.

No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.

Prigge ES, Urban K, Stiegler S, Müller M, Kloor M, Mai S, Ottstadt M, Lohr F, Wenz F, Wagner S, Wittekindt C, Klussmann JP, Hampl M, von Knebel Doeberitz M, Reuschenbach M.

Hum Pathol. 2014 Nov;45(11):2347-54. doi: 10.1016/j.humpath.2014.08.001. Epub 2014 Aug 23.

PMID:
25257576
11.

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.

Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R.

Cell Cycle. 2015;14(14):2355-61. doi: 10.1080/15384101.2015.1053669. Epub 2015 Jun 1.

12.

Sequencing the head and neck cancer genome: implications for therapy.

Sun W, Califano JA.

Ann N Y Acad Sci. 2014 Dec;1333:33-42. doi: 10.1111/nyas.12599. Epub 2014 Dec 1. Review.

13.

The mutational landscape of head and neck squamous cell carcinoma.

Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR.

Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.

14.

Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.

Wu ES, Park JY, Zeitouni JA, Gomez CR, Reis IM, Zhao W, Kwon D, Lee E, Nelson OL, Lin HY, Franzmann EJ, Savell J, McCaffrey TV, Goodwin WJ, Hu JJ.

Head Neck. 2016 Aug;38(8):1234-41. doi: 10.1002/hed.24420. Epub 2016 Mar 29.

PMID:
27028310
15.

Comprehensive mutation analysis of PIK3CA, p14ARF, p16INK4a and p21Waf1/Cip1 genes is suggestive of a non- neoplastic nature of phenytoin induced gingival overgrowth.

Swamikannu B, Kumar KS, Jayesh RS, Rajendran S, Muthupalani RS, Ramanathan A.

Asian Pac J Cancer Prev. 2013;14(5):2743-6.

16.

Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.

Todorova TA, Jordanov SH, Stancheva GS, Chalakov IJ, Melnicharov MB, Kunev KV, Mitev VI, Kaneva RP, Goranova TE.

Pathol Oncol Res. 2015 Apr;21(2):413-21. doi: 10.1007/s12253-014-9836-0. Epub 2014 Aug 23.

PMID:
25149524
17.

Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.

Ali SM, Pal SK, Wang K, Palma NA, Sanford E, Bailey M, He J, Elvin JA, Chmielecki J, Squillace R, Dow E, Morosini D, Buell J, Yelensky R, Lipson D, Frampton GM, Howley P, Ross JS, Stephens PJ, Miller VA.

Oncologist. 2016 Jan;21(1):33-9. doi: 10.1634/theoncologist.2015-0241. Epub 2015 Dec 15.

18.

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D.

Epigenetics. 2014 Jul;9(7):1031-46. doi: 10.4161/epi.29025. Epub 2014 May 1.

19.

Molecular characterization of oral squamous cell carcinoma using targeted next-generation sequencing.

Er TK, Wang YY, Chen CC, Herreros-Villanueva M, Liu TC, Yuan SS.

Oral Dis. 2015 Oct;21(7):872-8. doi: 10.1111/odi.12357. Epub 2015 Aug 6.

PMID:
26173098
20.

No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours.

Jefferies S, Edwards SM, Hamoudi RA, A'Hern R, Foulkes W, Goldgar D, Eeles R; MPT Collaborators.

Br J Cancer. 2001 Nov 2;85(9):1383-6.

Supplemental Content

Support Center